Immune thrombocytopenia

What is Immune thrombocytopenia?

Immune thrombocytopenia (ITP) is a rare autoimmune blood disorder in which the body’s immune system mistakenly attacks and destroys platelets, the blood cells responsible for clotting. This destruction leads to dangerously low platelet counts, causing easy bruising, bleeding, and characteristic skin spots called petechiae. ITP affects approximately 2-5 people per 100,000 individuals globally, with both children and adults susceptible to the condition. While the exact trigger remains unknown in most cases, ITP can significantly impact quality of life but is manageable with proper medical care and treatment.

Key statistics

Symptoms

Common symptoms: Petechiae, easy bruising, nosebleeds, gum bleeding, heavy menstrual periods, fatigue.

The hallmark symptoms of ITP stem from the reduced ability of blood to clot properly. Petechiae appear as small, pinpoint red or purple spots on the skin, particularly on the legs and feet. These differ from typical bruises as they don’t blanch when pressed. Easy bruising occurs with minimal trauma, often resulting in large, dark bruises from minor bumps. Mucosal bleeding manifests as frequent nosebleeds, bleeding gums during brushing, or blood blisters inside the mouth.

Women may experience unusually heavy or prolonged menstrual periods. Fatigue can develop due to chronic blood loss or the body’s immune response. In severe cases, patients may experience gastrointestinal bleeding, visible as blood in vomit or dark, tarry stools. The most serious complication is intracranial bleeding, which occurs in less than 1% of cases but represents a medical emergency. Unlike other blood disorders, ITP patients typically don’t experience enlarged lymph nodes or spleen enlargement.

Submit Your Paper

Causes and risk factors

ITP is an acquired autoimmune condition, meaning it develops during a person’s lifetime rather than being inherited. The immune system produces antibodies that mistakenly target platelets, marking them for destruction by the spleen. This process reduces platelet lifespan from the normal 8-10 days to just a few hours.

Primary ITP occurs without an identifiable underlying cause, representing about 80% of adult cases. Secondary ITP can be triggered by various factors including viral infections (Epstein-Barr virus, cytomegalovirus, hepatitis C, HIV), certain medications (quinine, sulfonamides, vancomycin), autoimmune diseases (systemic lupus erythematosus, antiphospholipid syndrome), or certain cancers (chronic lymphocytic leukemia, lymphomas).

Risk factors include female gender, recent viral infection, family history of autoimmune diseases, and certain genetic predispositions involving immune system regulation genes. Helicobacter pylori infection has been associated with ITP in some populations, particularly in Mediterranean and Asian countries.

Prevention

Currently, there are no evidence-based methods to prevent ITP, as it is an acquired autoimmune condition with largely unknown triggers. Unlike genetic disorders, ITP cannot be prevented through genetic testing or carrier screening, as it is not inherited.

However, individuals diagnosed with ITP can take preventive measures to reduce bleeding risks. These include avoiding medications that affect platelet function (such as aspirin and certain pain relievers), using soft-bristled toothbrushes, wearing protective gear during activities, and maintaining good oral hygiene to prevent gum bleeding. Regular monitoring with healthcare providers helps prevent serious complications through early intervention when platelet counts drop dangerously low.

Complications

Without proper treatment, ITP can lead to several serious complications. The most concerning is severe bleeding, particularly intracranial hemorrhage, which occurs in approximately 0.5-1% of patients and can be fatal. Chronic blood loss may lead to iron deficiency anemia, causing additional fatigue and weakness.

Prolonged bleeding episodes can require emergency medical intervention and blood transfusions. Gastrointestinal bleeding, while less common than mucosal bleeding, can be life-threatening if not promptly addressed. In women, severe menstrual bleeding can significantly impact quality of life and may require hormonal intervention.

Long-term complications may include the development of refractory ITP, where the condition becomes resistant to standard treatments. Some patients may require splenectomy, which increases lifelong infection risk. Additionally, chronic disease management can lead to psychological impacts including anxiety and depression.

Diagnosis

ITP diagnosis is primarily one of exclusion, as there is no single definitive test. The process begins with a complete blood count (CBC) showing isolated thrombocytopenia (platelet count typically below 100,000/μL) with otherwise normal red and white blood cell counts and morphology.

Physical examination focuses on bleeding signs, absence of splenomegaly, and lymph node assessment. A peripheral blood smear examination confirms low platelet numbers and normal platelet morphology. Bone marrow biopsy may be performed in older patients or atypical cases to rule out other causes, typically showing normal or increased megakaryocytes (platelet-producing cells).

Additional tests help exclude secondary causes: comprehensive metabolic panel, liver function tests, thyroid function, vitamin B12 and folate levels, and autoimmune markers including antinuclear antibodies. HIV, hepatitis B and C, and H. pylori testing may be indicated based on risk factors. Antiplatelet antibody tests are not routinely recommended as they lack sensitivity and specificity for diagnosis.

Treatment

Treatment approaches for ITP depend on platelet count, bleeding severity, and patient factors. First-line therapy typically includes prednisone or other corticosteroids, which suppress the immune response. Intravenous immunoglobulin (IVIG) provides rapid but temporary platelet count increases by blocking antibody-mediated platelet destruction.

Second-line treatments include thrombopoietin receptor agonists such as eltrombopag (oral) and romiplostim (subcutaneous injection), which stimulate platelet production. Fostamatinib, a spleen tyrosine kinase inhibitor, offers an alternative mechanism by reducing platelet destruction.

Rituximab, a monoclonal antibody targeting B cells, may be used in refractory cases. Splenectomy remains an option for patients unresponsive to medical therapy, with response rates of 60-70%. Emergency treatments for severe bleeding include platelet transfusions, high-dose IVIG, and intravenous anti-D immunoglobulin in Rh-positive patients.

Treatment goals focus on achieving safe platelet counts (typically >30,000/μL) rather than normal levels, balancing bleeding risk with treatment side effects.

Prognosis

The prognosis for ITP varies significantly between children and adults. In children, approximately 80% achieve spontaneous remission within 6-12 months, with acute ITP often resolving without long-term consequences. Adult ITP tends to be chronic, with only 10-20% experiencing spontaneous remission.

With appropriate treatment, most adults achieve adequate platelet counts and normal life expectancy. Approximately 60-70% of patients respond well to first-line treatments, while others may require multiple treatment modalities. The 10-year survival rate exceeds 95% in most studies, with bleeding-related mortality remaining low with proper management.

Quality of life can be excellent with effective treatment, though some patients experience treatment-related side effects. Factors associated with better prognosis include younger age at diagnosis, higher initial platelet count, and absence of bleeding symptoms. Refractory ITP, affecting 10-15% of patients, requires specialized management but new treatment options continue to emerge.

Quality of life

Living with ITP requires lifestyle adjustments but doesn’t prevent most normal activities. Patients should avoid high-contact sports and activities with significant bleeding risk when platelet counts are low. Regular dental care with soft brushes and gentle flossing helps prevent gum bleeding. Electric razors are safer than manual ones.

Dietary modifications aren’t typically required, though adequate iron intake helps prevent anemia from chronic bleeding. Some patients benefit from avoiding alcohol, which can affect platelet function. Regular exercise is generally encouraged, with modifications based on current platelet counts and bleeding risk.

Mental health support is important, as chronic illness can impact emotional well-being. Many patients experience anxiety about bleeding episodes or treatment side effects. Support groups and counseling can provide valuable coping strategies. Workplace accommodations may include avoiding tasks with injury risk or allowing time for medical appointments.

Sleep quality may be affected by steroid treatments or anxiety about the condition. Stress management techniques, including meditation and relaxation exercises, can be beneficial for overall well-being and may positively impact immune function.

Pregnancy and fertility

ITP doesn’t typically affect fertility, but pregnancy requires specialized management due to bleeding risks during delivery and potential effects on the newborn. Maternal antibodies can cross the placenta, potentially causing temporary thrombocytopenia in 10-15% of newborns.

Safe delivery planning depends on maternal platelet count, with levels above 80,000/μL generally considered safe for vaginal delivery and above 100,000/μL for cesarean section. Treatment during pregnancy focuses on corticosteroids and IVIG, as these are considered safest for the developing fetus.

Some medications used for ITP are not recommended during pregnancy. Eltrombopag and romiplostim have limited pregnancy data, while rituximab crosses the placenta and may affect fetal B cell development. Careful coordination between hematologists and obstetricians ensures optimal outcomes for both mother and baby.

Breastfeeding considerations depend on maternal medications, with some treatments potentially affecting nursing infants. Most women with well-controlled ITP have successful pregnancies with appropriate medical management.

Children

Childhood ITP often presents differently than adult disease, typically following viral infections and having an acute onset with severe thrombocytopenia. The “wait and see” approach is often appropriate in children, as most cases resolve spontaneously within months.

Treatment in children focuses on preventing serious bleeding rather than achieving normal platelet counts. Emergency treatment is reserved for severe bleeding or extremely low counts (12 months) may require ongoing management similar to adults. Special considerations include growth monitoring with steroid use, school activity modifications, and family education about bleeding precautions. Psychological support helps children and families cope with activity restrictions and medical procedures.

Most children with ITP can attend school and participate in modified activities. Contact sports and playground activities may need restriction based on platelet counts and bleeding history.

When to see a doctor

Seek immediate emergency care for signs of serious bleeding: severe headaches, vision changes, confusion, vomiting blood, black or bloody stools, or heavy bleeding that won’t stop. These may indicate life-threatening internal bleeding requiring urgent intervention.

Schedule urgent medical appointments for new or worsening petechiae, large bruises from minor trauma, frequent nosebleeds, or unusual bleeding from gums or other sites. Women should report significant changes in menstrual bleeding patterns.

Routine follow-up is essential for monitoring platelet counts and treatment effectiveness. Patients should maintain regular contact with their hematologist and report any new symptoms or medication side effects. Annual influenza vaccination is recommended, though live vaccines should be avoided in patients receiving immunosuppressive treatments.

Regular monitoring allows for treatment adjustments and early intervention when needed, preventing serious complications and optimizing quality of life.

Regional context

Limited specific data exists for ITP prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries. Some studies suggest geographic variations in H. pylori-associated ITP, with higher rates reported in Mediterranean populations. Regional dietary factors and genetic variations may influence disease presentation and treatment response.

Healthcare infrastructure and treatment availability may vary across the region, potentially affecting access to newer therapies like thrombopoietin receptor agonists. The Global Medical Journal welcomes contributions from regional hematologists and patient advocates to better understand ITP patterns and treatment outcomes in these populations.

Cultural factors may influence bleeding perception and healthcare-seeking behaviors, making patient education particularly important in diverse populations.

Research and clinical trials

Current research focuses on understanding ITP pathogenesis, developing targeted therapies, and improving treatment outcomes. Novel approaches include complement inhibitors, Bruton’s tyrosine kinase inhibitors, and immunomodulatory agents targeting specific immune pathways.

Gene therapy research explores methods to enhance platelet production or modify immune responses. Biomarker studies aim to identify patients most likely to respond to specific treatments, enabling personalized medicine approaches.

Ongoing clinical trials investigate combination therapies, new drug formulations, and treatment sequencing strategies. ClinicalTrials.gov lists current studies examining innovative approaches for both newly diagnosed and refractory ITP patients.

Recent breakthroughs include better understanding of megakaryocyte biology and immune tolerance mechanisms. Patient registries and real-world evidence studies help optimize treatment guidelines and identify long-term outcomes.

Frequently asked questions

Is ITP contagious or hereditary?

No, ITP is neither contagious nor directly inherited. It’s an acquired autoimmune condition that develops during a person’s lifetime, though genetic factors may influence immune system function and disease susceptibility.

Can ITP be cured completely?

While some patients, particularly children, experience permanent remission, most adult cases require ongoing management rather than cure. With proper treatment, most people achieve safe platelet counts and live normal lives.

What platelet count is considered dangerous?

Platelet counts below 10,000/μL significantly increase bleeding risk, especially for spontaneous bleeding. Counts below 50,000/μL may require treatment before surgery or dental procedures. Individual bleeding risk varies among patients.

Can I exercise and play sports with ITP?

Exercise is generally beneficial, but high-contact sports should be avoided when platelet counts are low. Swimming, walking, and low-impact activities are usually safe. Always discuss activity restrictions with your healthcare provider based on current platelet levels.

Will I need treatment for life?

Treatment duration varies greatly among patients. Some achieve remission and can discontinue therapy, while others require ongoing treatment. Regular monitoring helps determine the minimum effective treatment needed to maintain safe platelet counts.

Support and resources

International organizations:
– Platelet Disorder Support Association (PDSA) – Primary patient advocacy organization for ITP
– Orphanet – Comprehensive rare disease database and resources
– National Organization for Rare Disorders (NORD)
– EURORDIS – Rare Diseases Europe
– World Health Organization (WHO) – Global health information and guidelines

Professional organizations:
– International Society on Thrombosis and Haemostasis (ISTH)
– American Society of Hematology (ASH)
– European Hematology Association (EHA)

Related conditions

– Thrombotic thrombocytopenic purpura
– Hemolytic uremic syndrome
– Aplastic anemia
–

Cite this page

GMJ News Desk. “Immune thrombocytopenia.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/immune-thrombocytopenia/

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.